Market Cap (In TWD)
787.98 Million
Revenue (In TWD)
805 Thousand
Net Income (In TWD)
-68.15 Million
Avg. Volume
89.07 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 15.4-25.8
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- TW0006917008
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ming-Wen Lee
- Employee Count
- -
- Website
- https://www.andros.com.tw
- Ipo Date
- 2023-01-12
- Details
- Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
More Stocks
-
CNBZCNB Corporation
CNBZ
-
MBX
-
NWL
-
SQM-B
-
6555
-
SFBC
-
MLYNFMalayan Banking Berhad
MLYNF
-
WJX